To probe the therapeutic potential of all the synthesized derivatives, CCK-8 (Cell Counting Kit-8) assay was performed to evaluate the in vitro antiproliferative activities of all the new compounds against four human NSCLC cell lines: H460 and A549 express wild type EGFR (Helfrich et al., 2006); PC-9 is sensitive to Erlotinib and characterized by expressing EGFR exon 19 deletion mutation (ΔE746-A750) (Chmielecki et al., 2011); H1975 harbored the EGFR-activating mutations L858R but also the T790M mutation, which is associated with Erlotinib resistance (Helfrich et al., 2006). This evidence concerns the gene EGFR and non-small cell lung carcinoma.